Stempeutics receives US process patent for its novel stem cell drug Stempeucel

Will help patients suffering from Critical Limb Ischemia (CLI)

Stempeutics Research, a group company of Manipal Education and Medical Group and a joint venture with Cipla Group, announced that the United States Patent and Trademarks Office (USPTO) granted a US process patent for its novel stem-cell based drug Stempeucel. Stempeucel will initially be used for the treatment of CLI and is a breakthrough treatment option which directly addresses the root cause of the disease, unlike other drugs which typically treat the symptoms and not the disease itself.

Critical Limb Ischemia (CLI) is a progressive form of peripheral arterial disease, which blocks the arteries in the lower extremities, resulting into reduction of the blood flow. It is a debilitating disease which affects patients with severe pain in the feet or toes.

Stempeucel is derived from allogeneic pooled mesenchymal stromal cells extracted from the bone marrow of healthy, adult voluntary donors. The company proprietary pooling approach allows an efficient manufacturing process with minimum wastage of resources in order to provide the product at an affordable cost to patients. This approach also allows more than one million patient doses from a single set of master cell banks, which is unique in regenerative medicine. The proprietary technology allows Stempeucel to extend the therapeutic potential of the drug across multiple disease categories.

Commenting on the US patent, BN Manohar, Chief Executive Officer, Stempeutics said, “The patent granted by USPTO is a strong recognition for Stempeutics for its sustained excellence of scientific and clinical work and underscores the global leadership in allogeneic, pooled MSC technology. We believe that the Stempeucel product is a game-changer offering an advanced therapeutic treatment for millions of patient suffering with this dreadful disease.”

Chandru Chawla, Head, Cipla New Ventures said, “Through Cipla Group’s investment in Stempeutics, we are demonstrating a firm commitment bringing the next generation of biologics in order to address unmet medical needs. With this novel Stempeucel technology, we are supporting Stempeutics discovery of this first-of-its-kind regenerative medicine.”

EP News BureauMumbai